Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176748 · ClinicalTrials.gov registry record · Phase 2
Treatment for Patients With Metastatic Thyroid Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00176748 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 3 participants.
The verdict
NCT00176748, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is being done to find out the good and bad effects of an investigational drug that is not approved for sale, called AG-013736. Tumors need blood vessels in order to continue to grow, and AG-013736 is thought to work by playing a role in preventing new blood vessels from growing. We want to see if AG-013736 has any effect on your disease by making your tumor smaller and if so, for how long. We also want to test the safety \[the effect on your body\] of AG-013736 and to measure the amount of AG-013736 that gets into your blood. AG-013736 has been given to over 140 patients with cancer on other studies.
Interventions
- DRUG AG 6013736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176748
The ClinicalTrials.gov registry entry for NCT00176748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG 6013736 is the first listed.
NCT00176748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176748 about?
NCT00176748 is a clinical study titled "Treatment for Patients With Metastatic Thyroid Cancer". This study is being done to find out the good and bad effects of an investigational drug that is not approved for sale, called AG-013736. Tumors need blood vessels in order to continue to grow, and AG-013736 is thought to work by playing a role in preventing new blood vessels from growing. We want t...
What is the current status of trial NCT00176748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2005-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00176748?
The interventions under investigation include: AG 6013736 (DRUG).
Who is sponsoring clinical trial NCT00176748?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.